Literature DB >> 9765432

High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.

H Mochizuki1, J P Schwartz, K Tanaka, R O Brady, J Reiser.   

Abstract

Previously we designed novel pseudotyped high-titer replication defective human immunodeficiency virus type 1 (HIV-1) vectors to deliver genes into nondividing cells (J. Reiser, G. Harmison, S. Kluepfel-Stahl, R. O. Brady, S. Karlsson, and M. Schubert, Proc. Natl. Acad. Sci. USA 93:15266-15271, 1996). Since then we have made several improvements with respect to the safety, flexibility, and efficiency of the vector system. A three-plasmid expression system is used to generate pseudotyped HIV-1 particles by transient transfection of human embryonic kidney 293T cells with a defective packaging construct, a plasmid coding for a heterologous envelope (Env) protein, and a vector construct harboring a reporter gene such as neo, ShlacZ (encoding a phleomycin resistance/beta-galactosidase fusion protein), HSA (encoding mouse heat-stable antigen), or EGFP (encoding enhanced green fluorescent protein). The packaging constructs lack functional Vif, Vpr, and Vpu proteins and/or a large portion of the Env coding region as well as the 5' and 3' long terminal repeats, the Nef function, and the presumed packaging signal. Using G418 selection, we routinely obtained vector particles pseudotyped with the vesicular stomatitis virus G glycoprotein (VSV-G) with titers of up to 8 x 10(7) CFU/microgram of p24, provided that a functional Tat coding region was present in the vector. Vector constructs lacking a functional Tat protein yielded titers of around 4 x 10(6) to 8 x 10(6) CFU/microgram of p24. Packaging constructs with a mutation within the integrase (IN) core domain profoundly affected colony formation and expression of the reporter genes, indicating that a functional IN protein is required for efficient transduction. We explored the abilities of other Env proteins to allow formation of pseudotyped HIV-1 particles. The rabies virus and Mokola virus G proteins yielded high-titer infectious pseudotypes, while the human foamy virus Env protein did not. Using the improved vector system, we successfully transduced contact-inhibited primary human skin fibroblasts and postmitotic rat cerebellar neurons and cardiac myocytes, a process not affected by the lack of the accessory proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765432      PMCID: PMC110304     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer.

Authors:  M L Liu; B L Winther; M A Kay
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.

Authors:  P A Goepfert; K L Shaw; G D Ritter; M J Mulligan
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  Origin of the HIV-susceptible human CD4+ cell line H9.

Authors:  D L Mann; S J O'Brien; D A Gilbert; Y Reid; M Popovic; E Read-Connole; R C Gallo; A F Gazdar
Journal:  AIDS Res Hum Retroviruses       Date:  1989-06       Impact factor: 2.205

6.  Inducible human immunodeficiency virus type 1 packaging cell lines.

Authors:  H Yu; A B Rabson; M Kaul; Y Ron; J P Dougherty
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles.

Authors:  J Reiser; G Harmison; S Kluepfel-Stahl; R O Brady; S Karlsson; M Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

8.  Helper virus-free transfer of human immunodeficiency virus type 1 vectors.

Authors:  J H Richardson; J F Kaye; L A Child; A M Lever
Journal:  J Gen Virol       Date:  1995-03       Impact factor: 3.891

9.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Integration of murine leukemia virus DNA depends on mitosis.

Authors:  T Roe; T C Reynolds; G Yu; P O Brown
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  112 in total

1.  A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

Authors:  N Srinivasakumar; F G Schuening
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.

Authors:  Z Lai; I Han; G Zirzow; R O Brady; J Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

4.  In vivo assessment of gene delivery to keratinocytes by lentiviral vectors.

Authors:  Ulrich Kuhn; Atsushi Terunuma; Wolfgang Pfutzner; Ruth Ann Foster; Jonathan C Vogel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells.

Authors:  Zhennan Lai; Ina Han; Misun Park; Roscoe O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 6.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

7.  Identification of a novel proliferation-inducing determinant using lentiviral expression cloning.

Authors:  Dmitri Chilov; Cornelia Fux; Hana Joch; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

8.  CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.

Authors:  Mariko Nakano; Edward J Kelly; Constanze Wiek; Helmut Hanenberg; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2012-07-06       Impact factor: 4.436

9.  Optimal Expression of the Envelope Glycoprotein of Orthobornaviruses Determines the Production of Mature Virus Particles.

Authors:  Madoka Sakai; Yoko Fujita; Ryo Komorizono; Takehiro Kanda; Yumiko Komatsu; Takeshi Noda; Keizo Tomonaga; Akiko Makino
Journal:  J Virol       Date:  2020-12-02       Impact factor: 5.103

10.  Efficient transient genetic manipulation in vitro and in vivo by prototype foamy virus-mediated nonviral RNA transfer.

Authors:  Martin V Hamann; Nicole Stanke; Erik Müllers; Kristin Stirnnagel; Sylvia Hütter; Benedetta Artegiani; Sara Bragado Alonso; Federico Calegari; Dirk Lindemann
Journal:  Mol Ther       Date:  2014-05-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.